The aim of the present study was to correlate MRS measurements, including NAA, in patients with SCA2, SCA3, or SCA6 with CAG repeat number and SARA scores, with the goal of establishing a novel method for the prediction of SCA onset and progression, which might help guide the optimization of neuroprotective therapies. The gene discussed is ATXN2; the disease is autosomal dominant cerebellar ataxia.